This clinical trial is focused on studying the effects of a new treatment called NMD670 for patients with Myasthenia Gravis. Myasthenia Gravis is a condition that causes weakness in the muscles that control movements, often affecting the eyes, face, and swallowing. The study will test three different dose levels of NMD670, which is taken as a tablet, to see how well it works and how safe it is for patients.

The purpose of the study is to evaluate the effectiveness and safety of NMD670 over a period of 21 days. Participants will be randomly assigned to receive either NMD670 or a placebo, which looks like the real medication but does not contain the active substance. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the trial.

Throughout the study, participants will take the medication orally and will be monitored by healthcare professionals to assess any changes in their condition. The main goal is to observe any improvements in muscle strength and overall symptoms of Myasthenia Gravis. The study aims to provide valuable information on the potential benefits of NMD670 for managing this condition.